Journal of Leukocyte Biology· 2020Q2· Review
ICAM-1: A master regulator of cellular responses in inflammation, injury resolution, and tumorigenesis
- 966citations
- Q2SCImago
- 2020year
Short summary
ICAM-1, a cell surface receptor, is newly recognized not only for its role in leukocyte recruitment during inflammation but also as a master regulator of epithelial injury resolution and immune cell function in tumorigenesis.
AI-generated from the title and abstract; the full text is not read.
Key points
- ICAM-1 regulates leukocyte recruitment to inflammatory sites.
- It is also expressed on epithelial and immune cells, acting as a biosensor.
- Emerging roles include epithelial injury resolution and immune cell function in tumorigenesis.
- Past attempts to inhibit ICAM-1 for injury resolution have failed.
AI-generated from the title and abstract; the full text is not read.
Abstract
ICAM-1 is a cell surface glycoprotein and an adhesion receptor that is best known for regulating leukocyte recruitment from circulation to sites of inflammation. However, in addition to vascular endothelial cells, ICAM-1 expression is also robustly induced on epithelial and immune cells in response to inflammatory stimulation. Importantly, ICAM-1 serves as a biosensor to transduce outside-in-signaling via association of its cytoplasmic domain with the actin cytoskeleton following ligand engagement of the extracellular domain. Thus, ICAM-1 has emerged as a master regulator of many essential cellular functions both at the onset and at the resolution of pathologic conditions. Because the role of ICAM-1 in driving inflammatory responses is well recognized, this review will mainly focus on newly emerging roles of ICAM-1 in epithelial injury-resolution responses, as well as immune cell effector function in inflammation and tumorigenesis. ICAM-1 has been of clinical and therapeutic interest for some time now; however, several attempts at inhibiting its function to improve injury resolution have failed. Perhaps, better understanding of its beneficial roles in resolution of inflammation or its emerging function in tumorigenesis will spark new interest in revisiting the clinical value of ICAM-1 as a potential therapeutic target.
The authors' abstract, as published at the source. Journal of Leukocyte Biology, 2020 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
Field: Immunology and Allergy
Immunology and AllergyMedicine